Clinical Trial Results:
A Prospective, Multicenter, Double-Blind, Placebo-Controlled, Dose-Finding Phase-II Study for the Efficacy and Safety of LAIS® House Dust Mites Sublingual Tablets in Patients with Mite-Induced Allergic RhinoConjunctivitis Without or With Controlled Asthma using a Titrated Nasal Provocation Test model.
Summary
|
|
EudraCT number |
2017-005079-21 |
Trial protocol |
DE |
Global completion date |
04 Feb 2020
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
26 Sep 2021
|
First version publication date |
26 Sep 2021
|
Other versions |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.